Alterations in glycosylation as biomarkers for cancer detection

Journal of Clinical Pathology

Volumn 63, Issue 4, 2010, Pages 322-329

  Reis, Celso A ^a,b   Osorio, Hugo ^a   Silva, Luisa ^a   Gomes, Catarina ^a   David, Leonor ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOHYDRATE ANTIGEN; GLYCAN; GLYCOCONJUGATE; GLYCOLIPID; GLYCOPROTEIN; MUCIN; SIALYL LEWIS X ANTIGEN; TUMOR MARKER;

BIOSYNTHESIS; BLOOD GROUP LEWIS SYSTEM; CANCER DIAGNOSIS; HUMAN; HUMAN CELL CULTURE; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; REVIEW; SEROLOGY;

ANTIGENS, NEOPLASM; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; LEWIS BLOOD-GROUP SYSTEM; NEOPLASM PROTEINS; NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950410995     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.071035     Document Type: Review

References (142)

1. Hakomori S. Aberrant glycosylation in cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985;45:2405-2414
2. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco)lipid metabolism. Cancer Res 1996;56:5309-5318 (Pubitemid 27011703)
3. Zhao Y, Takahashi M, Gu J, et al. Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci 2008;99:1304-1310
4. Clausen H, Bennett EP. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. Glycobiology 1996;6:635-646 (Pubitemid 26386377)
5. Hassan H, Reis CA, Bennett EP, et al. The lectin domain of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities. J Biol Chem 2000;275:38197-38205 (Pubitemid 32009138)
6. Ten Hagen KG, Fritz TA, Tabak LA. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 2003;13:1R-16R.
7. Homa FL, Hollander T, Lehman DJ, et al. Isolation and expression of a cDNA clone encoding a bovine UDP-GalNAc:polypeptide N- acetylgalactosaminyltransferase. J Biol Chem 1993;268:12609-12616 (Pubitemid 23182423)
8. White T, Bennett EP, Takio K. Purification and cDNA cloning of a human UDP-Nacetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. J Biol Chem 1995;270:24156-24165
9. Bennett EP, Hassan H, Clausen H. cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N- acetylgalactosaminyltransferase, Gal-NAc-T3. J Biol Chem 1996;271:17006-17012 (Pubitemid 26244245)
10. Hagen FK, Ten Hagen KG, Beres TM. cDNA cloning and expression of a novel UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase. J Biol Chem 1997;272:13843-13848 (Pubitemid 27224824)
11. Bennett EP, Hassan H, Mandel U, et al. Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNActransferases in complete O-glycosylation of the MUC1 tandem repeat. J Biol Chem 1998;273:30472-30481 (Pubitemid 28545522)
12. Bennett EP, Hassan H, Hollingsworth MA, et al. A novel human UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, GalNAc-T7, with specificity for partial GalNAc-glycosylated acceptor substrates. FEBS Lett 1999;460:226-230 (Pubitemid 29495945)
13. Bennett EP, Hassan H, Mandel U, et al. Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-Dgalactosamine: Polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy. J Biol Chem 1999;274:25362-25370 (Pubitemid 129530703)
14. Ten Hagen KG, Hagen FK, Balys MM, et al. Cloning and expression of a novel, tissue specifically expressed member of the UDP-Gal-NAc:polypeptide N-acetylgalactosaminyltransferase family. J Biol Chem 1998;273:27749-27754
15. Ten Hagen KG, Tetaert D, Hagen FK, et al. Characterization of a UDP-Gal-NAc: polypeptide N-acetylgalactosaminyltransferase that displays glycopeptide N-acetylgalactosaminyltransferase activity. J Biol Chem 1999;274:27867-27874 (Pubitemid 129527842)
16. Ten Hagen KG, Bedi GS, Tetaert D, et al. Cloning and characterization of a ninth member of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family, ppGaNTase-T9. J Biol Chem 2001;276:17395-17404 (Pubitemid 37411552)
17. Guo JM, Zhang Y, Cheng L, et al. Molecular cloning and characterization of a novel member of the UDP-GalNAc:polypeptide N- acetylgalactosaminyltransferase family, pp-GalNAc-T12. FEBS Lett 2002;524:211-218
18. Schwientek T, Bennett EP, Flores C, et al. Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans, and mammals. One subfamily composed of l (2)35Aa is essential in Drosophila. J Biol Chem 2002;277:22623-22638
19. Wang H, Tachibana K, Zhang Y, et al. Cloning and characterization of a novel UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, pp-GalNAc-T14. Biochem Biophys Res Commun 2003;300:738-744 (Pubitemid 36268899)
20. Zhang Y, Iwasaki H, Wang H, et al. Cloning and characterization of a new human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen. J Biol Chem 2003;278:573-584 (Pubitemid 36043611)
21. Mandel U, Hassan H, Therkildsen MH, et al. Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family. Glycobiology 1999;9:43-52. (Pubitemid 29041603)
22. Gomes J, Marcos NT, Berois N, et al. Expression of UDP-N-acetyl- Dgalactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 in Gastric Mucosa, Intestinal Metaplasia, and Gastric Carcinoma. J Histochem Cytochem 2009;57:79-86.
23. Wandall HH, Hassan H, Mirgorodskaya E, et al. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. J Biol Chem 1997;272:23503-23514 (Pubitemid 27410917)
24. Sutherlin ME, Nishimori I, Caffrey T, et al. Expression of three UDP-N-acetylalpha-D-galactosamine:polypeptide GalNAc N- acetylgalactosaminyltransferases in adenocarcinoma cell lines. Cancer Res 1997;57:4744-4748 (Pubitemid 27468980)
25. Brooks SA, Carter TM, Bennett EP, et al. Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer. Acta Histochem 2007;109:273-284
26. Rajpert-De Meyts E, Poll SN, Goukasian I. Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation. Virchows Arch 2007;451:805-814 (Pubitemid 47497945)
27. Kohsaki T, Nishimori I, Nakayama H, et al. Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer. J Gastroenterol 2000;35:840-848
28. Hanisch FG, Reis CA, Clausen H, et al. Evidence for glycosylation- dependent activities of polypeptide N-acetylgalactosaminyltransferases rGalNAc-T2 and -T4 on mucin glycopeptides. Glycobyology 2001;11:731-740 (Pubitemid 32976346)
29. Shibao K, Izumi H, Nakayama Y, et al. Expression of UDP-N-acetyl-alpha- Dgalactosamine- polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer 2002;94:1939-1946 (Pubitemid 34270046)
30. Freire T, Berois N, Sóñora C, et al. UDP-N-acetyl-D- galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. Int J Cancer 2006;119:1383-1388 (Pubitemid 44258815)
31. Brockhausen I, Yang J, Dickinson N, et al. Enzymatic basis for sialyl-Tn expression in human colon cancer cells. Glyconj J 1998;15:595-603. (Pubitemid 28330772)
32. Brockhausen I, Yang J, Lehotay M, et al. Pathways of mucin O-glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancer-associated Sialyl-Tn antigen expression. Biol Chem 2001;382:219-232 (Pubitemid 32243930)
33. Marcos NT, Pinho S, Grandela C, et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res 2004;64:7050-7057 (Pubitemid 39331016)
34. Sewell R, Backstrom M, Dalziel M, et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem 2006;281:3586-3594 (Pubitemid 43845976)
35. Dalziel M, Whitehouse C, McFarlane I, et al. The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem 2001;276:11007-11015 (Pubitemid 38089281)
36. Dennis JW. Core 2 GlcNAc-transferase and polylactosamine expression in O-glycans. Glycobiology 1993;3:91-93
37. Bierhuizen MF, Maemura K, Fukuda M. Expression of a differentiation antigen and poly-N-acetyllactosaminyl O-glycans directed by a cloned core 2 beta-1,6-N-acetylglucosaminyltransferase. J Biol Chem 1994;269:4473-4479 (Pubitemid 24237816)
38. Schwientek T, Nomoto M, Levery SB, et al. Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1,6-N- acetylglucosaminyltransferase forming core 2 and core 4. J Biol Chem 1999;274:4504-4512 (Pubitemid 129501455)
39. Nakayama J, Yeh JC, Misra AK, et al. Expression cloning of a human alpha1,4-N-acetylglucosaminyltransferase that forms GlcNAcalpha1->4Galbeta- >R, a glycan specifically expressed in the gastric gland mucous cell-type mucin. Proc Natl Acad Sci U S A 1999;96:8991-8996 (Pubitemid 29374695)
40. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52:257-331.
41. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 1985;314:53-57
42. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res 1996;56:2237-2244 (Pubitemid 26154066)
43. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997;14:569-576 (Pubitemid 27353200)
44. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nature Rev Cancer 2005;5:526-542
45. Ju T, Lanneau GS, Gautam T, et al. Human tumor antigens Tn and sialyl Tn arise from mutations in cosmc. Cancer Res 2008;68:1636-1646
46. Nakasaki H, Mitomi T, Noto T, et al. Mosaicism in the expression of tumor-associated carbohydrate antigens in human colonic and gastric cancer. Cancer Res 1989;49:3662-3669
47. David L, Nesland JM, Clausen H, et al. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. APMIS Suppl 1992;27:162-172
48. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nature Rev Cancer 2004;4:45-60.
49. Burchell J, Durbin H, Taylor-Papadimitriou J. Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J Immunol 1983;131:508-513
50. Gendler SJ, Burchell JM, Duhig T, et al. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci U S A 1987;84:6060-6064
51. Gum JR, Hicks JW, Swallow DM, et al. Molecular cloning of cDNAs derived from a novel human intestinal mucin gene. Biochem Biophys Res Commun 1990;171:407-415
52. Gum JR, Crawley SC, Hicks JW, et al. MUC17, a novel membrane-tethered mucin. Biochem Biophys Res Commun 2002;291:466-475
53. Toribara NW, Roberton AM, Ho SB, et al. Human gastric mucin Identi fication of a unique species by expression cloning. J Biol Chem 1993;268:5879-5885
54. Porchet N, Pigny P, Buisine MP, et al. Human mucin genes: genomic organization and expression of MUC4, MUC5AC and MUC5B. Biochem Soc Trans 1995;23:800-805
55. Bobek LA, Tsai H, Biesbrock AR, et al. Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7). J Biol Chem 1993;268:20563-20569
56. Shankar V, Pichan P, Eddy RL Jr, et al. Chromosomal localization of a human mucin gene (MUC8) and cloning of the cDNA corresponding to the carboxy terminus. Am J Respir Cell Mol Biol 1997;16:232-241 (Pubitemid 127497445)
57. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-27375 (Pubitemid 37410652)
58. Moniaux N, Nollet S, Porchet N, et al. Complete sequence of the human mucin MUC4: a putativel cell membrane-associated mucin. Biochem J 1999;338:325-333 (Pubitemid 129512255)
59. Williams SJ, Wreschner DH, Tran M, et al. MUC13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J Biol Chem 2001;276:18327-18336 (Pubitemid 37411406)
60. Carvalho F, Seruca R, David L, et al. MUC1 gene polymorphism and gastric cancer - na epidemiological study. Glycoconj J 1997;14:107-111 (Pubitemid 27104501)
61. Santos-Silva F, Fonseca A, Caffrey T, et al. Thomsen-Friedenreich antigen expression in gastric carcinomas is associated with MUC1 mucin VNTR polymorphism. Glycobiol 2004;15:511-517 (Pubitemid 41214396)
62. Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999;59:1003-1007 (Pubitemid 29135958)
63. Reis CA, David L, Carvalho F, et al. Immunohistochemical study of the expression of MUC6 mucin and co-expression of other secreted mucins (MUC5AC and MUC2) in human gastric carcinomas. J Histochem Cytochem 2000;48:377-388 (Pubitemid 30131684)
64. Swartz MJ, Batra SK, Varshney GC, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 2002;117:791-796
65. Mesquita P, Almeida R, Lunet N, et al. Metaplasia e a transdifferentiation process that facilitates cancer development: the model of gastric intestinal metaplasia. Crit Rev Oncog 2006;12:13-26.
66. Ferreira B, Marcos NT, David L, et al. Terminal alpha1,4-linked N-acetylglucosamine in Helicobacter pylori-associated intestinal metaplasia of the human stomach and gastric carcinoma cell lines. J Histochem Cytochem 2006;54:585-591
67. Hakomori S. Glycosylation defining cancer malignacy: New wine in an old bottle. Proc Natl Acad Sci USA 2002;99:10231-10233
68. Springer GF. General carcinoma auto-antigens. Science 1984;224:1198-1206
69. Burchell JM, Mungul A, Taylor-Papadimitriou J, et al. O-linked glycosylation in the mammary gland: Changes that occur during malignancy. J Mammary Gland Biol Neoplasia 2001;6:355-364 (Pubitemid 39600493)
70. Cao Y, Stosiek P, Springer GF, et al. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 1996;106:197-207. (Pubitemid 26281400)
71. Kjeldsen T, Clausen H, Hirohashi S, et al. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988;48:2214-2222
72. Springer GF, Desai PR, Banatwala I. Blood group MN antigens and precursors in normal and malignant breast glandular tissue. J Natl Cancer Inst 1975;54:335-339
73. Ikeda Y, Kuwano H, Baba K, et al. Expression of Sialyl-Tn antigens in normal squamous epithelium, dysplasia, and squamous cell carcinoma in the esophagus. Cancer Res 1993;53:1706-1708 (Pubitemid 23113256)
74. Itzkowitz SH, Yuan M, Montgomery CK, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197-204.
75. Schuessler MH, Pintado S, Welt S, et al. Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int J Cancer 1991;47:180-187
76. Itzkowitz S, Kjeldsen T, Friera A, et al. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 1991;100:1691-1700
77. Noguchi M, Nakajima T, Hirohashi S, et al. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Hum Pathol 1989;20:53-57
78. Inoue M, Ogawa H, Tanizawa O, et al. Immunodetection of sialyl-Tn antigen in normal, hyperplastic and cancerous tissues of the uterine endometrium. Virchows Arch A Pathol Anat Histopathol 1991;418:157-162
79. Ravn V, Mandel U, Svenstrup B, et al. Simple mucin-type carbohydrates in normal and malignant human endometrium. Int J Gynecol Pathol 1995;14:158-166
80. Inoue M, Ton SM, Ogawa H, et al. Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary. Am J Clin Pathol 1991;96:711-716
81. Nishiyama T, Matsumoto Y, Watanabe H, et al. Detection of Tn antigen with Vicia villosa agglutinin in uranira bladder cancer: its relevance to the patient's clinical course. J Natl Cancer Inst 1987;78:1113-1118
82. Springer GF. Tn epitope (N-acetyl-D-galactosamine alpha-O-serine/ threonine) density in primary breast carcinoma: a functional predictor of aggressiveness. Mol Immunol 1989;26:1-5.
83. Itzkowitz SH, Bloom EJ, Kokal WA, et al. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990;66:1960-1966
84. Ma XC, Terata N, Kodama M, et al. Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. Eur J Cancer 1993;29A:1820-1823
85. Werther JL, Rivera-MacMurray S, Bruckner H, et al. Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br J Cancer 1994;69:613-616 (Pubitemid 24076492)
86. Marcos NT, Cruz A, Silva F, et al. Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines. J Histochem Cytochem 2003;51:761-771 (Pubitemid 36628857)
87. Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, et al. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J 2001;18:883-893 (Pubitemid 36315053)
88. Julien S, Adriaenssens E, Ottenberg K, et al. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006;16:54-64. (Pubitemid 43009808)
89. Pinho S, Marcos NT, Ferreira B, et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett 2007;249:157-170 (Pubitemid 46452924)
90. Sørensen AL, Reis CA, Tarp MA, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006;16:96-107.
91. Lindesmith L, Moe CL, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003;9:548-553 (Pubitemid 36597100)
92. Azevedo M, Eriksson S, Mendes N, et al. Infection by Helicobacter pylori expressing the BabA adhesin is influenced by the secretor phenotype. J Pathol 2008;215:308-316
93. Fukuta S, Magnani JL, Gaur PK, et al. Monoclonal antibody CC3C195, which detects cancer-associated antigens in serum, binds to the human Lea blood group antigen and to its sialylated derivative. Arch Biochem Biophys 1987;255:214-216
94. Hirohashi S, Shimosato Y, Ino Y, et al. Distribution of blood group antigens and CA 19-9 in gastric cancers and non-neoplastic gastric mucosa. Gann 1984;75:540-547
95. Chia D, Terasaki PI, Suyama N, et al. Use of monoclonal antibodies to sialylated Lewisx and sialylated Lewisa for serological tests of cancer. Cancer Res 1985;45:435-437
96. Hansson GC. Zopf DBiosynthesis of the cancer-associated sialyl-Lea antigen. J Biol Chem 1985;260:9388-9392
97. Holmes EH, Ostrander GK, Hakomori S. Biosynthesis of the sialyl-Lex determinant carried by type 2 chain glycosphingolipids (IV3NeuAcIII3FucnLc4, VI3NeuAcV3FucnLc6, and VI3NeuAcIII3V3Fuc2nLc6) in human lung carcinoma PC9 cells. J Biol Chem 1986;261:3737-3743
98. Akamatsu S, Yasawa S, Tachikawa S, et al. Alpha 2->3sialyltransferase associated with the synthesis of CA 19-9 in colorectal tumors. Cancer 1996;77:1694-1700 (Pubitemid 26111854)
99. Majuri ML, Niemela R, Tiisala S, et al. Expression and function of alpha 2,3-sialyl and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Int J Cancer 1995;63:551-559
100. Hiraiwa N, Hiraiwa M, Kannagi R. Human T-cell leukemia virus-1 encoded Tax protein transactivates alpha 1->3 fucosyltransferase Fuc-T VII, which synthesizes sialyl Lewis X, a selectin ligand expressed on adult T-cell leukemia cells. Biochem Biophys Res Commun 1997;231:183-186 (Pubitemid 27212134)
101. Matsushita Y, Cleary KR, Ota DM, et al. Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. Lab Invest 1990;63:780-791
102. Hanski C, Drechsler K, Hanisch FG, et al. Altered glycosylation of the MUC-1 protein core contributes to the colon carcinoma-associated increase of mucin-bound sialyl-Lewis(x) expression. Cancer Res 1993;53:4082-4088
103. Berg EL, Robinson MK, Mansson O, et al. A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem 1991;266:14869-14872
104. Takada A, Ohmori K, Takahashi N, et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochem Biophys Res Commun 1991;179:713-719
105. Kim YJ, Borsig L, Varki NM, et al. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 1998;95:9325-9330 (Pubitemid 28506230)
106. Borsig L, Wong R, Hynes RO, et al. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2002;99:2193-2198 (Pubitemid 34169037)
107. Fukuoka K, Narita N, Saijo N. Increased expression of sialyl Lewis(x) antigen is associated with distant metastasis in lung cancer patients: immunohistochemical study on bronchofiberscopic biopsy specimens. Lung Cancer 1998;20:109-116
108. Tatsumi M, Watanabe A, Sawada H, et al. Immunohistochemical expression of the sialyl Lewis x antigen on gastric cancer cells correlates with the presence of liver metastasis. Clin Exp Metastasis 1998;16:743-750 (Pubitemid 29170484)
109. Nakamori S, Kameyama M, Imaoka S, et al. Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Dis Colon Rectum 1997;40:420-431
110. Baldus SE, Zirbes TK, Monig SP, et al. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: Sialosyl-Lewis(a), sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biol 1998;19:445-453
111. Nakamori S, Nishihara S, Ikehara Y, et al. Molecular mechanism involved in increased expression of sialyl Lewis antigens in ductal carcinoma of the pancreas. J Exp Clin Cancer Res 1999;18:425-432
112. Amado M, Carneiro F, Seixas M, et al. Dimeric sialyl-Le(x) expression in gastric carcinoma correlates with venous invasion and poor outcome. Gastroenterology 1998;114:462-470
113. Grabowski P, Mann B, Mansmann U, et al. Expression of SIALYL-Le(x) antigen defined by MAb AM-3 is an independent prognostic marker in colorectal carcinoma patients. Int J Cancer 2000;88:281-286
114. Sarkar AK, Rostand KS, Jain RK, et al. Fucosylation of disaccharide precursors of sialyl LewisX inhibit selectin-mediated cell adhesion. J Biol Chem 1997;272:25608-25616
115. Weston BW, Hiller KM, Mayben JP, et al. Expression of human alpha(1,3) fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells. Cancer Res 1999;59:2127-2135
116. Hirai M, Minematsu H, Kondo N, et al. Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem Biophys Res Commun 2007;353:553-558 (Pubitemid 46048704)
117. Nustad K, Bast RC Jr, Brien TJ, et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996;17:196-219. (Pubitemid 26227618)
118. O'Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348-366
119. Yin BW, Dnistrian A, Lloyd KO, et al. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 2002;98:737-740 (Pubitemid 34225625)
120. Chang A, Cai J, Miranda G, et al. Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder. J Urol 2004;172:2182-2186 (Pubitemid 39507487)
121. Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006;42:1-41.
122. Baskić D, Ristić P, Matić S, et al. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. Biomarkers 2007;12:657-667
123. Sevinc A, Adli M, Kalender ME, et al. Benign causes of increased serum CA-125 concentration. Lancet Oncol 2007;8:1054-1055 (Pubitemid 350182965)
124. Harris L, Fritsche H, Mennel R. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5531
125. Zurawski VR Jr, Orjaseter H, Andersen A, et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988;42:677-680
126. Pauler DK, Menon U, McIntosh M. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:489-493 (Pubitemid 32701635)
127. Gostout BS, Brewer MA. Guidelines for referral of the patient with an adnexal mass. Clin Obstet Gynecol 2006;49:448-458
128. Ebeling FG, Stieber P, Untch M, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;86:1217-1222
129. Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002;76:95-102.
130. Uehara M, Kinoshita T, Hojo T, et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008;13:447-451
131. Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol 2001;76:266-271 (Pubitemid 32381683)
132. Lauro S, Trasatti L, Bordin F, et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 1999;19:3511-3515 (Pubitemid 30000212)
133. Safi F, Schlosser W, Kolb G, et al. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997;1:106-112 (Pubitemid 127433827)
134. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327
135. Reiter W, Stieber P, Reuter C, et al. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 1997;17:2903-2906
136. Ychou M, Duffour J, Kramar A, et al. Clinical significance and prognostic value of CA72-4 compared with CEA and CA 19-9 in patients with gastric cancer. Dis Markers 2000;16:105-110. (Pubitemid 32591564)
137. Marrelli D, Pinto E, De Stefano A, et al. Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. J Surg Oncol 2001;78:253-258 (Pubitemid 33097056)
138. Carpelan-Holmström M, Louhimo J, Stenman UH, et al. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004;66:296-302. (Pubitemid 38822799)
139. Louhimo J, Kokkola A, Alfthan H, et al. Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer. Int J Cancer 2004;111:929-933 (Pubitemid 39096242)
140. Louhimo J, Alfthan H, Stenman UH, et al. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 2004;66:126-131
141. Bakalakos EA, Burak WE Jr, Young DC, et al. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases? Am J Surg 1999;177:2-6.
142. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23:338-351 (Pubitemid 41656973)